Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation  by Sakakibara, Yutaka et al.
Prevascularization with gelatin microspheres containing
basic fibroblast growth factor enhances the benefits of
cardiomyocyte transplantation
Yutaka Sakakibara, MDa
Kazunobu Nishimura, MD, PhDa
Keiichi Tambara, MDa
Masaya Yamamoto, PhDb
Fanglin Lu, MDa
Yasuhiko Tabata, PhDb
Masashi Komeda, MD, PhDa
Objective: The effects of cell transplantation on the ischemic failing heart have
already been documented. However, the area in and around infarct regions is not a
good environment for cells to survive in because they are exposed to poor conditions
in which certain requirements cannot be adequately supplied. We therefore designed
a study to investigate the efficacy of prevascularization in ischemic regions before
cell transplantation.
Methods: Rats with myocardial infarction were randomized into 4 groups: 11 rats
received a culture medium injection to the left ventricular wall (control group), 11
received fetal cardiomyocyte transplantation (TX group), 11 received gelatin hy-
drogel microspheres incorporating basic fibroblast growth factor (FGF group), and
11 received basic fibroblast growth factor pretreatment sequentially, followed by
cardiomyocyte transplantation (FGF-TX group). Four weeks later, left ventricular
function was assessed by means of echocardiography and cardiac catheterization.
Results: In the FGF and FGF-TX groups neovascularization was found in the scar
tissue 1 week later. The TX, FGF, and FGF-TX groups showed better fractional
shortening than the control group (TX, FGF, FGF-TX, and control: 28%  4.4%,
24%  8.6%, 27%  7.3%, and 17%  4.6%, respectively; P  .01). Left
ventricular maximum time-varying elastance was higher in the FGF-TX group than
in the TX and FGF groups (FGF-TX, TX, and FGF: 0.52  0.23, 0.30  0.08, and
0.27  0.20 mm Hg/L, respectively; P  .01). Histologically, more transplanted
cells survived in the FGF-TX group than in the TX group.
Conclusions: Prevascularization with basic fibroblast growth factor–incorporated
microspheres enhances the benefits of cardiomyocyte transplantation. We expect
that this system will contribute to regeneration medicine through its extensive
application to other growth factors.
The number of patients with end-stage heart failure has been increas-ing. Presently, cardiac transplantation is believed to be the besttreatment for most of these patients. However, the paucity of donorsrepresents a significant problem. In North America, for instance,only less than 20% of transplantation candidates can receive donorhearts. Therefore, alternative treatments for end-stage heart failure
are being sought.
In this context a number of studies have been reported on cell transplantation. Li
and colleagues1,2 and Scorcin and coworkers3,4 showed that cardiomyocyte trans-
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plantation was effective in improving left ventricular (LV)
function in rat myocardial infarction models. Other studies
also reported the improvement of cardiac performance after
transplantation of noncardiomyocyte cells (eg, skeletal
myoblasts, smooth muscle cells, and mesenchymal stem
cells derived from bone marrow).5-9 Although these findings
implied the efficacy of cell transplantation, no studies, to the
best of our knowledge, have focused on the adjuncts to
improve the environment of transplanted cells exposed to
ischemia, inflammation, and oxidative stress when they are
transplanted into the ischemic or peri-ischemic regions.
Cell-growth factors, such as basic fibroblast growth fac-
tor (bFGF) and vascular endothelial growth factor (VEGF),
are known to greatly contribute to neovascularization in the
ischemic tissue area. They should be released over a long
period of time at the site of action to obtain rich neovascu-
larization. However, this has not always been successful,
mainly because of their very short half-life in vivo. A
number of strategies have been reported to overcome this
problem by using protein release systems on the basis of
polymer matrices. Because proteins are easily denatured
and lose their biologic activities when exposed to harsh
environments during the formulation process with a poly-
mer matrix, it is necessary to exploit new formulation meth-
ods to induce slow release of proteins under mild conditions
to minimize their denaturation. We previously documented
that polymer hydrogels are a preferable matrix candidate for
release of growth factors because of their biosafety and high
inertness toward protein drugs.10 Subsequently, biodegrad-
able gelatin microspheres incorporating bFGF have been
developed with acidic gelatin hydrogels, enabling the re-
lease of bFGF at the site of action over a period of time
adequate for effective neovascularization.11,12
In the present study we investigated whether prevascu-
larization of infarct or peri-infarct LV regions with this
controlled release system of bFGF enhances the effects of
cell transplantation in a rat myocardial infarction model.
Materials and Methods
Syngeneic Lewis rats weighing 250 to 290 g were used in this
study. The study protocol was approved by the Kyoto University
Ethics Committee for Animal Research. All animals received
humane care in compliance with the “Principles of Laboratory
Animal Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal Re-
sources, National Research Council, and published by the National
Academy Press.
Preparation of bFGF-incorporating Gelatin Hydrogels
Human recombinant bFGF with an isoelectric point of 9.6 was
supplied by Kaken Pharmaceutical Co (Tokyo, Japan). A gelatin
sample with an isoelectric point of 5.0 was isolated from the
bovine bone through the alkaline process (Nitta Gelatin Co, Osaka,
Japan). Radioisotope Na125I (740 MBq/mL in 0.1 N NaOH aque-
ous solution) and N-succinimidyl-3-(4-hydroxy-3,5–di[125I]-iodo-
phenyl) propionate (Bolton-Hunter reagent, 147 MBq/mL) were
purchased from NEN Research Products (DuPont, Wilmington,
Del). The bFGF microspheres were prepared as described previous-
ly.11 Briefly, gelatin microspheres were prepared through glutaralde-
hyde cross-linking of gelatin in aqueous solution dispersed in an oil
phase. Then the microspheres were washed with acetone (4°C) and
recovered by means of centrifugation at 5000 rpm and 4°C for 5
minutes. The obtained microspheres were finally washed by means of
centrifugation with double-distilled water and freeze-dried. The aver-
age diameter of the microspheres was 10 m. bFGF was radioiodi-
nated according to the method of Greenwood and colleagues.13
In Vivo Evaluation of bFGF Release and Gelatin
Hydrogel Degradation
Gelatin hydrogels incorporating 125I-labeled bFGF were implanted
subcutaneously into the backs of mice. As a control, 100 L of
aqueous solution of 125I-labeled bFGF was subcutaneously in-
jected into the mouse back. The mice were killed at intervals, and
the skin around the bFGF-implanted or injected site was cut into
strips. The facia was thoroughly wiped off with filter paper. The
remaining radioactivity of gelatin hydrogel, excised skin, and filter
paper was measured on a gamma counter (ARC-301B; Aloka Co,
Ltd, Tokyo, Japan) to evaluate the time profile of in vivo degra-
dation of the gelatin hydrogels.
Cardiomyocyte Isolation and Culture Procedures
Ventricular cardiomyocytes were isolated from syngeneic Lewis
fetal rat (Japan SLC Inc, Shizuoka, Japan) hearts and cultured as
previously described.14 In brief, 20-day-old embryos hearts were
removed and washed in phosphate-buffered saline solution. The
minced ventricles were incubated in phosphate-buffered saline
solution containing trypsin (0.25%), collagenase (0.05%), and
glucose (0.02%) at 37°C for 15 minutes. The cell suspension was
transferred into Iscove’s modified Dulbecco’s medium (Gibco
Laboratory, Life Technologies, Grand Island, NY) supplemented
with 10% fetal bovine serum, 0.1 mmol/L -mercaptoethanol, 100
U/mL penicillin, and 100 g/mL streptomycin. The cell suspen-
sion was centrifuged at 500g for 5 minutes, and the cell pellet was
resuspended in culture medium. At this stage, cardiomyocytes
were purified by using a preplating method. Before each transplan-
tation, all cells were labeled with fluorescent dyes with a PKH 26
Red Fluorescent Cell Linker Kit (Sigma Chemical Co, St. Louis,
Mo) for general cell membrane labeling.
Chronic Myocardial Infarction Model
Male Lewis rats were orally intubated into the trachea after being
anesthetized with ethyl ether gas. Anesthesia was maintained dur-
ing the operation with 1% to 1.5% isoflurane. The proximal left
anterior descending coronary artery was ligated proximally with a
5-0 polypropylene suture.15,16 An ST-segment elevation on elec-
trocardiography and color changes in the LV muscle were noted in
all rats. Four weeks after the LAD ligation, infarction size and
cardiac function were evaluated by means of echocardiography, as
described below.17,18
Experimental Groups
Four weeks after the LAD ligation, the hearts were exposed by a
lateral rethoracotomy after achievement of general anesthesia, as
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described in the myocardial infarction model above. Forty-four
rats were randomized into 4 groups: 11 rats received an intramyo-
cardial injection of only culture medium (control group), 11 re-
ceived fetal cardiomyocyte transplantation (TX group), 11 re-
ceived an injection of gelatin hydrogel microspheres incorporating
bFGF (bFGF microspheres, FGF group), and 11 received bFGF
microsphere injection, followed by sequential fetal cardiomyocyte
transplantation 1 week later (FGF-TX group).
Cell Transplantation or bFGF Microsphere Injection
In each group the volume of the injected solution was 50 L. In the
TX and FGF groups 6  106 cultured fetal cardiomyocytes and
bFGF microspheres, respectively, were injected with a fine syringe
into the center of the scar tissue of the LV free wall. In the
FGF-TX group bFGF microsphere injection and the following
cardiomyocyte transplantation were performed by using the same
method as above.
Assessment of the LV Function
LV function was assessed by means of echocardiography (SONOS
5500 Imaging System; Agilent Technologies, Andover, Mass).
Images were recorded from the left parasternal windows in the
right lateral decubitus position. The following parameters were
measured and derived from the B- and M-mode tracing: LV
end-diastolic dimension (in millimeters), LV end-systolic dimen-
sion (in millimeters), fractional shortening (percentage), and frac-
tional area change.19 Infarction size was estimated by using the
percentage of the akinetic region divided by the LV endocardial
circumference on a midventricular short-axis view at end diasto-
le.20 One day after echocardiographic evaluation, all rats had more
precise assessment of global LV function before death.17,18 A 2Fr
micromanometer-tipped catheter (Millar Instruments Inc, Houston,
Tex) was inserted into the LV through the right carotid artery, and
a 3F occlusion balloon catheter was inserted into the inferior vena
cava (IVC) through the right iliac vein to occlude the IVC. LV
pressure and its first time derivative (dP/dt) were continuously
monitored through the arterial catheter by using a multiple record-
ing system. Two-dimensionally targeted M-mode echocardio-
grams were obtained along the short-axis view of the left ventricle
at the level of the papillary muscles to calculate LV systolic
Figure 1. Experimental protocol. 1st Op, Ligation of the left anterior descending coronary artery; Treatment I, culture
medium injection or fetal cardiomyocyte transplantation or injection of gelatin hydrogel microspheres incorpo-
rating bFGF (bFGF microsphere injection); Treatment II, bFGF microsphere injection followed by fetal cardiomyo-
cyte transplantation; Echo, echocardiography; Cath, measurement of the LV pressure with a micromanometer-
tipped catheter; and Hist, histologic study.
Figure 2. In vivo release of bFGF and gelatin hydrogels. Patterns
of declining radioactivity in the back subcutis of mice after
subcutaneous implantation of 125I-labeled bFGF in solution (open
triangles), in hydrogels (open circles), and in 125I-labeled gelatin
hydrogels (filled circles).
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volume from LV end-systolic dimension by the cube formula.
During IVC occlusion with the balloon, LV pressure waveforms
and M-mode tracings were simultaneously recorded on the same
monitor. The end-systolic pressure-volume points obtained from
echocardiography and cardiac catheterization were subjected to
least-squared linear regression, and the LV maximum time-varying
elastance (in millimeters of mercury per microliter) was calculated
as the slope of the fitted line. The time constant of isovolumic
relaxation ( [in milliseconds]  LV pressure at peak negative/
dp/dt) as an index of global systolic and diastolic function was
calculated. LV end-diastolic pressure (in millimeters of mercury)
was measured at the same time. Figure 1 shows the study protocol,
including the operation and sampling points in each group.
Histologic Study
After final assessment, all rats were killed, and the hearts were
removed for histologic study. The specimens were separated in
halves by the short-axis section, including the injection point; one
part was fixed with 10% formalin for hematoxylin and eosin
staining, and the other part was cryopreserved for staining with
PKH26. Then sections were microscopically examined with the
use of fluorescence microscopy for PKH26 dye. Five rats with bFGF
microsphere injection and 5 with culture medium injection only were
also prepared as above in addition to the follow-up study groups to
quantify the neovascularization associated with bFGF pretreatment.
They were killed, and the hearts were extirpated a week after each
treatment. Heart sections of 10-m thickness were prepared and
TABLE I. Cardiac function data obtained by means of echocardiography among the control, TX, FGF, and FGF-TX groups
Control group TX group FGF group FGF-TX group
Before treatment
LVDd (mm) 10.3 0.8 10.1 0.7 9.7 0.9 9.7 0.9
LVDs (mm) 7.9 2.2 7.8 0.9 7.9 1.1 7.8 1.0
FS (%) 18.8 5.4 22.4 5.4 19.1 6.7 19.8 4.1
FAC (%) 25.9 3.3 26.8 6.6 28.2 6.5 28.2 4.6
HR (beats/min) 373 32 364 31 359 47 372 43
Infarction size (%) 27.4 2.9 27.0 4.1 30.8 5.3 29.3 4.0
After treatment
LVDd (mm) 10.7 0.6 10.0 1.1 9.5 0.7† 9.6 0.6*
LVDs (mm) 8.8 0.7 7.2 0.9† 7.2 1.1† 7.0 1.0†
FS (%) 17.3 4.6 28.4 4.4† 24.5 8.6 27.4 7.3†
FAC (%) 22.5 4.3 34.0 11.9† 32.6 6.7* 41.7 6.8†‡
HR (beats/min) 357 31 374 36 363 40 376 56
Infarction size (%) 27.5 3.5 27.0 4.6 28.1 5.2 24.9 5.0
All values are shown as the means  SD.
LVDd, Left ventricular end-diastolic dimension; LVDs, end-systolic dimension; FS, fractional shortening; FAC, fractional area change; HR, heart rate;
Infarction size, the percentage of akinetic endocardial length to the whole left ventricular endocardial circumference.
*P  .05 vs control group.
†P  .01 vs control group.
‡P  .05 vs FGF group.
Figure 3. Indices of LV maximum time-varying elastance (LVEmax), LV end-diastolic pressure (LVEDP), and  in
hearts of mice from the control, TX, FGF, and FGF-TX groups 4 weeks after each treatment. Error bars show SEM.
The FGF-TX group shows a higher LVEmax than the other groups (*P < .05 and **P < .01 vs FGF-TX group). The
FGF-TX group shows a lower LVEDP than the other groups (†P < .05 vs control group). There was no significant
difference in  among the 4 groups.
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stained with hematoxylin and eosin. The vessels per unit of area (200
m2) in the scar and the peri-infarct region were counted in 5 fields
per each slide by 2 blinded pathologists. The average number of the
vessels in one field was used for statistical analysis.
Data Analysis
All values were shown as the mean values  SD. The pairwise
comparisons of individual group means were conducted by means
of the Tukey test. Statistical analyses were performed with Stat-
view for Windows version 5.0 (SAS Institute Inc, Cary, NC).
Results
Coronary artery ligation was performed in a total of 70 rats,
of which 12 died within a week. Four weeks later, echocar-
diography was performed on the survivors. Among them, 4
had no or a small myocardial infarction (infarct size,
20%), and 10 had large infarctions (infarct size, 40%).
The rats with moderate-size myocardial infarctions in the
anterior LV wall (n  44) were then enrolled in this study.
Each rat in the FGF and FGF-TX groups died immediately
after the injection of bFGF microspheres, and data from
these animals were excluded from analysis.
In Vivo Release of bFGF
Figure 2 shows the pattern of decreasing residual radioac-
tivity after subcutaneous implantation in the backs of mice
in gelatin hydrogels incorporating different 125I-labeled
bFGF. More than 80% of the bFGF injected as solution was
cleared from the injected site within 1 day. In marked contrast
there was prolonged release of bFGF from the hydrogel at the
site of implantation. In addition, there was a strong correlation
between the patterns of in vivo bFGF release and hydrogel
degradation, as seen in Figure 2. This result suggests that
bFGF, together with a fragment of gelatin molecules, is re-
leased as a result of hydrogel degradation.
Characterization and Identification of Graft Cells
Most of the isolated cells derived from fetal rat hearts were
observed to beat in culture medium and were composed of
more than 90% of cardiomyocytes, as determined by means
of immunostaining with alpha-sarcomeric muscle actin.
Transplanted cells were detected with PKH26 red fluores-
cent dye in each recipient heart.
In Vivo Cardiac Function
There was no significant difference among the 4 groups in
cardiac function and infarction size before treatment. Four
weeks after each treatment, LV end-diastolic dimension in
the FGF and FGF-TX groups was smaller than in the control
group. The TX, FGF, and FGF-TX groups had significantly
smaller LV end-systolic dimension than the control group.
These 3 groups had better fractional shortening and frac-
tional area change than the control group. These findings are
summarized in Table I. LV maximum time-varying elas-
tance in the FGF-TX group was 430% (P .01) higher than
in the control group and 172% (P  .05) higher than in the
TX group (Figure 3). LV end-diastolic pressure in the
FGF-TX group was the lowest and 55% lower than that in
the FGF-TX group (Figure 3). There was no significant
difference in  among the 4 groups (Figure 3).
Histology in the Recipient Heart
Microscopic examination showed the findings below. There
were many neovessels in and around the scar tissue 1 week
after the injection of bFGF microspheres (Figure 4). Vas-
cular densities in the scar and peri-infarction regions in the
specimens from the rats injected with bFGF microspheres
were higher than those from rats without bFGF treatment
(P  .001, Figure 4). Four weeks after cell transplantation,
transplanted cardiomyocytes labeled with PKH26 red fluo-
rescent dye were detected in the scar area. Whereas most of
the transplanted cells were found in the peri-infarction re-
Figure 4. A, Neovascularization in the scar tissue of the left
ventricle free wall 1 week after the injection of bFGF micro-
spheres. Arrow indicates neovessels. (Hematoxylin and eosin,
original magnification 100.) B, Capillary density in scar and
peri-infarct area in each treatment group (n  5) is expressed as
the number of capillary vessels per high-power field. Data are
shown as means  SEM. The bFGF treatment groups have a
higher capillary vessel density than the control group in both
areas (*P < .001).
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gions in the TX group, transplanted cells in the FGF-TX
group were detected in all scar areas, including infarct
regions, even in the middle of the scar (Figure 5, D and E).
Many vessels were found in and around transplanted tissue
in the FGF-TX group. The infarct LV wall was thicker in
the TX, FGF, and FGF-TX group than in the control group
(Figure 5, A-C).
Discussion
In this study cardiomyocyte transplantation was effective
for the ischemic failing heart. However, transplanted cells in
the control group survived only in the peri-infarct regions
and not in the scar area. On the other hand, in the FGF-TX
group many cardiomyocytes were found in the scar tissue,
and cardiac function in that group was much improved
compared with that in the TX group. We speculate that the
following mechanisms may account for these findings. First,
bFGF may have enhanced the viability of transplanted car-
diomyocytes because many more transplanted cells were
observed in histologic sections. It may be that in the
FGF-TX group neovascularization induced around the site
of infarction provided adequate oxygen, nutrition, and other
substances, such as growth factors. Second, bFGF may have
exerted several kinds of direct effects on transplanted fetal
cardiomyocytes. Pasumarthi and colleagues21 reported that
bFGF may stimulate DNA synthesis and myocyte prolifer-
ation and differentiation during development, favoring a
more fetal program of contractile gene expression.22,23
The results of the present study suggested the importance
of securing an adequate blood supply in the infarct and
peri-infarct LV regions for the transplanted cells to survive.
Recently, it was reported that myocardial angiogenesis by
means of gene transfer with transplanted cells improved
cardiac function in ischemic failing hearts. However, with
the genetic method, the effect of angiogenesis cannot be
started immediately after cell transplantation. In addition,
gene therapy may not be safe because of its side effects. In
view of these considerations, prevascularization with the
controlled release system with bFGF microspheres may
provide a unique environment that is favorable for various
transplanted cells in the treatment of heart failure with
myocardial infarction.
There are several limitations to the clinical application of
the present methodology. First, it may be technically de-
manding to inject bFGF microspheres into the scarred LV
wall, which is very thin. In our experiments 2 rats died
during the operative procedure. These deaths were probably
caused by misinjection of bFGF microspheres, with subse-
quent systemic embolization. Gelatin particles are 10 to 16
m in diameter, and in FGF solution they combined with
bFGF to form large particles. Because of this property, we
should be very careful to avoid the intraluminal administra-
tion of the microspheres. The risk of misinjection should be
reduced when microspheres are injected into the myocar-
dium of human subjects or large animals. Second, consid-
ering combined therapy, it may not be feasible to open the
Figure 5. A-C, Histologic findings 4 weeks after each treatment: A, control group; B, TX group; C, FGF-TX group.
(Hematoxylin and eosin staining, original magnification 1.) D and E, Fluorescent image of transplanted cells
labeled with PKH26 red fluorescent dye (D, peri-infarct area in the TX group; E, middle of the myocardial infarction
in the FGF-TX group). (Original magnification 40.)
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chest twice to inject bFGF and, later, myocardial cells.
Although in the clinical setting it might seem more practical
to inject bFGF and transplanted cells simultaneously, theo-
retically there should be some time lag to allow for the
development of neovascularization. Hence further research
is necessary to investigate new methods to inject bFGF
microspheres without operation.
Various methods have been reported for the stimulation
of angiogenesis in infarcted regions. These include the
introduction of genes encoding VEGF or bFGF and trans-
plantation of interstitial cells from bone marrow and vascu-
lar endothelial cells.24,25 We recently showed that gelatin
hydrogel microspheres incorporating bFGF facilitate angio-
genesis in infarcted regions.11,12 Although bFGF has a po-
tent angiogenic function, its half-life in vivo is very short. In
addition, it is likely that the injected free bFGF rapidly flows
away from the injection site. Therefore the injection of
bFGF in solution is not very effective in inducing vascular-
ization.11,12,26 In the method with bFGF-incorporating gel-
atin hydrogel microspheres, however, slowly released bFGF
exerts its activities and stimulates angiogenesis locally, with
the gelatin hydrogel microspheres being absorbed into the
living tissue. This system may induce angiogenesis suffi-
cient to supply essential requirements for cell survival be-
fore cell transplantation. With this system, biologically ac-
tive growth factors other than bFGF, such as hepatocyte
growth factor and VEGF, can be released as a result of in
vivo degradation of the hydrogels. Because the release
profile can be controllable by changing the water content of
gelatin hydrogels,10,11 we believe that this controlled release
system can contribute greatly to the progress of regeneration
medicine through its extensive application to other growth
factors.
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